在三阴性乳腺癌中,AR/ERK联合向通过FOXC2触发铁亡
Yuhan Zhao1, Chi Xu2, Yiqiu Liu1
1Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Science China. Life sciences
|September 20, 2025
概括
结合雄激素受体 (AR) 和ERK抑制剂显示出对三阴性乳腺癌 (TNBC) 治疗的前景. 这种新疗法诱导铁亡并通过向FOXC2信号通路来抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择的侵袭性亚型.
- 雄激素受体 (AR) 是一种潜在的治疗标,但AR抑制剂单疗显示出有限的疗效.
- 开发TNBC新型治疗策略至关重要.
研究的目的:
- 为了确定TNBC治疗的协同药物组合.
- 研究同时针对AR和ERK通路的治疗潜力.
- 阐明组合疗法诱导的细胞死亡的潜在机制.
主要方法:
- 进行了全面的药物库查,以确定有效的药物组合.
- 转录基因组测序被用来分析组合疗法的分子效应.
- 研究了关键的分子媒介,包括FOXC2和Hippo信号轴.
主要成果:
- ERK抑制剂GDC-0994与AR抑制剂比卡胺具有显著的协同作用.
- 组合疗法激活了铁灭,通过增加活性氧物种 (ROS),提高Fe2+水平和脂质过氧化表明.
- FOXC2被确定为一个关键的调解者,组合疗法抑制了FOXC2驱动的上皮质-介质细胞过渡 (EMT) 并通过FOXC2-Hippo信号轴诱导铁亡.
结论:
- 共同准AR和ERK途径代表了TNBC的一个有前途的治疗策略.
- 组合疗法通过诱导铁亡和抑制EMT来抑制瘤增殖,迁移和入侵.
- 这项研究为开发TNBC新型向治疗提供了基础.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Necrosis
6.2K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.2K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Adaptive Mechanisms in Cancer Cells
6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K

